In the BioHarmony Drug Report Database

"Preview" Icon

Nimodipine

Nimotop, Nymalize (nimodipine) is a small molecule pharmaceutical. Nimodipine was first approved as Nimotop on 1988-12-28. It is used to treat subarachnoid hemorrhage in the USA. The pharmaceutical is active against mineralocorticoid receptor. In addition, it is known to target cystic fibrosis transmembrane conductance regulator, voltage-dependent L-type calcium channel subunit alpha-1F, voltage-dependent L-type calcium channel subunit alpha-1D, voltage-dependent L-type calcium channel subunit alpha-1S, voltage-dependent L-type calcium channel subunit alpha-1C, and Ion transport protein. Nymalize’s patents are valid until 2038-04-16 (FDA).

 

Trade Name

 

Nimotop, Nymalize
 

Common Name

 

nimodipine
 

ChEMBL ID

 

CHEMBL1428
 

Indication

 

subarachnoid hemorrhage
 

Drug Class

 

Phenylpyridine vasodilators (nifedipine type)

Image (chem structure or protein)

Nimodipine structure rendering